Shanghai Rightongene Biotechnology Future Growth
Future criteria checks 5/6
Shanghai Rightongene Biotechnology is forecast to grow earnings and revenue by 62.5% and 24% per annum respectively. EPS is expected to grow by 62.3% per annum. Return on equity is forecast to be 1.7% in 3 years.
Key information
62.5%
Earnings growth rate
62.3%
EPS growth rate
| Biotechs earnings growth | 43.2% |
| Revenue growth rate | 24.0% |
| Future return on equity | 1.7% |
| Analyst coverage | Low |
| Last updated | 20 May 2024 |
Recent future growth updates
No updates
Recent updates
Shanghai Rightongene Biotechnology Co., Ltd.'s (SHSE:688217) Share Price Boosted 32% But Its Business Prospects Need A Lift Too
Oct 18
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Jul 23Investors Can Find Comfort In Shanghai Rightongene Biotechnology's (SHSE:688217) Earnings Quality
Apr 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 453 | 17 | N/A | 63 | 1 |
| 12/31/2025 | 375 | 14 | N/A | 41 | 1 |
| 12/31/2024 | 311 | 12 | N/A | 65 | 1 |
| 9/30/2024 | 249 | -5 | 1 | 48 | N/A |
| 6/30/2024 | 265 | 1 | -11 | 34 | N/A |
| 3/31/2024 | 266 | 7 | -56 | 20 | N/A |
| 12/31/2023 | 258 | 8 | -64 | 45 | N/A |
| 9/30/2023 | 351 | 23 | -43 | 101 | N/A |
| 6/30/2023 | 379 | 35 | -38 | 96 | N/A |
| 3/31/2023 | 433 | 44 | 5 | 107 | N/A |
| 12/31/2022 | 424 | 40 | -33 | 73 | N/A |
| 9/30/2022 | 354 | 41 | -40 | 34 | N/A |
| 6/30/2022 | 328 | 44 | -47 | 45 | N/A |
| 3/31/2022 | 274 | 29 | -47 | 61 | N/A |
| 12/31/2021 | 291 | 47 | -18 | 78 | N/A |
| 9/30/2021 | 289 | 53 | -17 | 66 | N/A |
| 6/30/2021 | 285 | 50 | 1 | 83 | N/A |
| 3/31/2021 | 307 | 53 | 16 | 84 | N/A |
| 12/31/2020 | 285 | 39 | 18 | 70 | N/A |
| 12/31/2019 | 255 | 36 | -42 | 12 | N/A |
| 12/31/2018 | 224 | 15 | -45 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688217 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: 688217 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688217 is expected to become profitable in the next 3 years.
Revenue vs Market: 688217's revenue (24% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688217's revenue (24% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688217's Return on Equity is forecast to be low in 3 years time (1.7%).